Dr Reddys Laboratories and US-based Gland Pharma have collaborated to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs).
The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the U.S.
According to IMS Health, the combined sale of branded and generic versions of the products in the U.S. is approximately US$ 1 Billion MAT for the most recent twelve months ending in August 2016.
Speaking on the opportunity, Alok Sonig, utive Vice President and Head of North America, Dr Reddys Lab said, Dr Reddys Laboratories has a strong track record in developing, marketing and distributing generic injectable in the U.S. Our strengths, combined with Glands track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.
Srinivas Sadu, Chief Operating Officer of Gland Pharma added, We are happy to expand our collaboration with Dr Reddys for marketing and distribution of Gland Products in US and other markets. Dr Reddys has an impressive track record of commercializing injectables products in the U.S, and we are confident that our partnership will continue to grow.
Dr Reddy’s is developing its US injectable business and has recently launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar.